Quantcast
Last updated on April 21, 2014 at 10:25 EDT

Latest Sufentanil Stories

2011-11-23 06:30:00

REDWOOD CITY Calif., Nov. 23, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the 23(rd) Annual Piper Jaffray Health Care Conference in New York City at the New York Palace Hotel. The presentation is scheduled for Tuesday,...

2011-11-03 15:05:00

CUPERTINO, Calif., Nov. 3, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2011. Total revenues were $8.1 million for the three months ended September 30, 2011 and 2010. Net loss for the three months ended September 30, 2011 was $5.0 million, compared to a net loss of $4.6 million for the same period in 2010. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) At September 30, 2011, we had cash...

2011-10-26 16:54:00

CUPERTINO, Calif., Oct. 26, 2011 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, November 3, 2011 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...

2011-09-28 06:30:00

REDWOOD CITY, Calif., Sept. 28, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX) ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that Mark G. Edwards has joined its Board of Directors. Mr. Edwards will also serve as the chairman of the Audit Committee. Mr. Edwards founded Deloitte Recap LLC (formerly, Recombinant Capital, Inc. "Recap"), a...

2011-09-15 06:30:00

REDWOOD CITY, Calif., Sept. 15, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at two separate investor conferences in New York City over the coming weeks as follows: UBS Global Life Sciences Conference Date: Tuesday, September...

2011-09-09 06:30:00

REDWOOD CITY, Calif., Sept. 9, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the Rodman & Renshaw Global Investment Conference in New York, NY at The Waldorf Astoria. The presentation is scheduled for Tuesday, September...

2011-09-06 06:30:00

CUPERTINO, Calif., Sept. 6, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the dosing of the last patient in the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER trial). POSIDUR is a post-operative pain relief depot that utilizes DURECT's patented SABER(TM) technology to deliver bupivacaine to provide up to three days of pain relief after surgery. DURECT expects to report top-line...

2011-08-25 06:30:00

REDWOOD CITY, Calif., Aug. 25, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the Southern California Investor Conference in Newport Beach, CA at The Island Hotel. The presentation is scheduled for Monday, August 29, 2011 at...

2011-08-11 06:30:00

REDWOOD CITY, Calif., Aug. 11, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the second quarter and six months ended June 30, 2011. Net loss for the second quarter of 2011 was $4.8 million, or $0.25 per share, compared with a net loss of $3.5 million, or $5.41 per...

2011-08-10 06:30:00

REDWOOD CITY, Calif., Aug. 10, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the Canaccord Genuity Growth Conference in Boston, MA at the InterContinental Hotel. The presentation is scheduled for Thursday, August 11, 2011 at...